8-K: BiomX Secures $3M Private Placement, Investor Gains Board Seat

BiomX Inc. announced a $3 million private placement of Series Y Convertible Preferred Stock and warrants, granting the investor a board seat and future participation rights.

Summary

• BiomX Inc. entered into a Securities Purchase Agreement on December 26, 2025, with an investor (Pyu Pyu Capital, LLC) for a private placement.
• The company will issue 3,300 shares of Series Y Convertible Preferred Stock with an aggregate stated value of $3.3 million.
• Warrants to purchase 3,300,000 shares of Common Stock will also be issued, representing 200% of the shares issuable upon conversion of the Series Y Preferred Stock.
• The transaction is expected to generate aggregate gross proceeds of $3.0 million for BiomX Inc.
• The Series Y Preferred Stock has an initial conversion price of $2.00 per share and pays a 15% annual dividend, payable quarterly in cash or Common Stock at the holder's election.
• The warrants are immediately exercisable with an initial exercise price of $2.00 per share and expire five years from issuance.
• The investor will gain the right to designate one director to the board immediately, and a second director after stockholder approval, provided certain beneficial ownership thresholds are met (9.99% and 19.99% respectively).
• Stockholder approval is required within 60 calendar days of closing for the issuance of Common Stock exceeding 19.99% of outstanding shares, as per NYSE American rules.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee, a 1.0% management fee, $25,000 for non-accountable expenses, and warrants for 99,000 shares of Common Stock with an exercise price of $2.50.
• A subsidiary, BiomX Ltd., initiated court-supervised insolvency proceedings on December 17, 2025.

Sentiment

Score: 3

Explanation: While the company secured needed capital, the terms are highly dilutive and expensive, coupled with the significant negative news of a subsidiary's insolvency, indicating substantial underlying challenges.

Positives

• Secured $3.0 million in gross proceeds, enhancing liquidity.
• The Series Y Preferred Stock offers a 15% annual dividend, providing attractive returns for the investor.
• The investor gains board representation, potentially bringing strategic guidance or oversight.
• The company has committed to maintaining a minimum cash balance of $1,000,000 for a specified period.

Negatives

• Significant dilution potential for existing common stockholders due to the issuance of preferred stock convertible into 3.3 million common shares and warrants for another 3.3 million common shares, plus placement agent warrants.
• The 15% dividend rate on preferred stock is high, representing a substantial ongoing cost or further dilution if paid in stock.
• The conversion and exercise prices of $2.00 for the preferred stock and warrants, and $2.50 for placement agent warrants, could be below the current market price, leading to immediate dilution.
• The insolvency proceedings of BiomX Ltd. indicate significant operational or financial distress within a subsidiary.
• The company incurs substantial placement agent fees and expenses (7% cash fee, 1% management fee, $25,000 expenses, and 99,000 warrants).

Risks

• Dilution Risk: The issuance of Series Y Preferred Stock and Warrants, and their potential conversion/exercise, could significantly dilute the ownership and voting power of existing common stockholders.
• Stockholder Approval Risk: Failure to obtain stockholder approval for the issuance of common stock exceeding 19.99% of outstanding shares could limit the investor's ability to convert/exercise, potentially triggering redemption rights or other adverse terms.
• Liquidity Risk: The company's ability to maintain the Minimum Cash Requirement of $1,000,000 is crucial, and failure to do so could trigger a Triggering Event.
• Operational/Financial Distress (Subsidiary): The court-supervised insolvency proceedings of BiomX Ltd. indicate significant challenges that could impact the parent company's overall financial health and operations.
• Market Price Volatility: The conversion and exercise prices are subject to adjustment based on the common stock's closing sale price, which could be negatively impacted by market conditions or the dilutive effect of this offering.
• Regulatory Compliance: Failure to comply with NYSE American rules regarding stockholder approval or SEC filing requirements could lead to penalties or delisting.
• Future Financing Restrictions: Restrictions on subsequent equity sales for 180 days post-Effective Date, with participation rights for the current investor, could limit the company's flexibility in raising future capital.

Future Outlook

The company expects the private placement to close around December 30, 2025. It intends to file a proxy statement with the SEC and hold a stockholders meeting within 60 calendar days of closing to approve the issuance of common stock exceeding 19.99% of outstanding shares. A resale registration statement for the newly issued securities is expected to be filed within 30 calendar days of closing and become effective within 60-90 days.

Industry Context

This capital raise provides BiomX with additional funding, which is critical for biotechnology companies often requiring substantial capital for R&D and operations. However, the insolvency proceedings of its subsidiary, BiomX Ltd., introduce a significant negative context, suggesting challenges specific to its Israeli operations or broader market conditions affecting its business model. The terms of the financing, including high dividend preferred stock and significant warrant coverage, reflect the company's current funding needs and potentially its risk profile within the competitive biotech landscape.

Comparison to Industry Standards

• The 15% annual dividend rate on the Series Y Preferred Stock is notably high, potentially indicating a higher risk profile or urgent need for capital compared to typical preferred stock offerings in more stable biotechnology companies.
• The issuance of warrants representing 200% of the common stock issuable upon preferred stock conversion, alongside the preferred stock, suggests a highly dilutive financing structure, which can be common for early-stage or distressed biotech firms but is generally less favorable than equity raises without such extensive warrant coverage.
• The placement agent fees (7% cash, 1% management, plus warrants) are within the higher range for private placements, especially for smaller companies or those perceived as higher risk, reflecting the cost of capital for BiomX.
• The beneficial ownership limitations (19.99%) and the requirement for stockholder approval for issuances exceeding this threshold are standard for NYSE American listed companies to prevent immediate change of control without shareholder consent.

Management Changes

Corporate Governance

Legal Proceedings

• BiomX Ltd., a subsidiary, initiated court-supervised insolvency proceedings pursuant to Israeli law on December 17, 2025. These proceedings are expected to involve the appointment of a trustee to oversee its winding-up or rehabilitation.

Stakeholder Impact

• Shareholders: Significant potential for dilution of existing common stockholders due to the issuance of convertible preferred stock and warrants. Voting power may also be diluted, although beneficial ownership limitations are in place. The high dividend rate on preferred stock could strain future cash flows or lead to further dilution if paid in stock.
• Creditors: The Series Y Preferred Stock ranks senior to common stock and Series X Preferred Stock, potentially impacting the recovery prospects of other equity holders in a liquidation event. The Minimum Cash Requirement provides some assurance of liquidity.
• Employees: The capital raise provides some financial runway, which could offer stability. However, the insolvency of a subsidiary might create uncertainty or lead to restructuring efforts.
• Customers/Suppliers: The capital raise may help ensure continued operations, but the subsidiary's insolvency could disrupt supply chains or product availability related to that entity.

Next Steps

• Closing of the private placement transactions on or about December 30, 2025.
• Filing of a proxy statement with the SEC.
• Holding a stockholders meeting within 60 calendar days of closing to approve the issuance of common stock exceeding 19.99% of outstanding shares.
• Filing a resale registration statement for the Registrable Securities within 30 calendar days of closing.
• Using commercially reasonable efforts to cause the resale registration statement to be declared effective by the SEC within 60-90 calendar days of closing.
• Maintaining a minimum cash balance of $1,000,000 until the first anniversary of the Closing Date or a Change of Control.

Key Dates

Recommendation

While the capital raise provides immediate liquidity, the terms are highly dilutive and expensive, featuring high-dividend preferred stock and extensive warrant coverage. This, combined with the significant negative news of a subsidiary entering court-supervised insolvency proceedings, points to substantial financial distress and operational challenges. The potential for further dilution and the high cost of capital suggest a deteriorating outlook for common shareholders, making a 'sell' recommendation appropriate for risk-averse investors.

Keywords

BiomX Inc., Private Placement, Series Y Preferred Stock, Warrants, Capital Raise, SEC Filing, Equity Financing, Dilution, Corporate Governance, Stockholder Approval, Insolvency, Biotechnology, PHGE, H.C. Wainwright & Co.